These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 18547758)

  • 1. Impairment of the in vitro drug release behaviour of oral modified release preparations in the presence of alcohol.
    Fadda HM; Mohamed MA; Basit AW
    Int J Pharm; 2008 Aug; 360(1-2):171-6. PubMed ID: 18547758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel dissolution method relevant to intestinal release behaviour and its application in the evaluation of modified release mesalazine products.
    Schellekens RC; Stuurman FE; van der Weert FH; Kosterink JG; Frijlink HW
    Eur J Pharm Sci; 2007 Jan; 30(1):15-20. PubMed ID: 17085024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiological bicarbonate buffers: stabilisation and use as dissolution media for modified release systems.
    Fadda HM; Merchant HA; Arafat BT; Basit AW
    Int J Pharm; 2009 Dec; 382(1-2):56-60. PubMed ID: 19666093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal release behaviour of modified-release drug products: dynamic dissolution testing of mesalazine formulations.
    Goyanes A; Hatton GB; Merchant HA; Basit AW
    Int J Pharm; 2015 Apr; 484(1-2):103-8. PubMed ID: 25721685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro dissolution of oral modified-release tablets and capsules in ethanolic media.
    Smith AP; Moore TW; Westenberger BJ; Doub WH
    Int J Pharm; 2010 Oct; 398(1-2):93-6. PubMed ID: 20667505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release.
    Andreas CJ; Chen YC; Markopoulos C; Reppas C; Dressman J
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):39-50. PubMed ID: 26391972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
    Christensen LA
    Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ethanol effects on drug release from Verapamil Meltrex, an innovative melt extruded formulation.
    Roth W; Setnik B; Zietsch M; Burst A; Breitenbach J; Sellers E; Brennan D
    Int J Pharm; 2009 Feb; 368(1-2):72-5. PubMed ID: 18992310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Biopredictive In Vitro Comparison of Oral Locally Acting Mesalazine Formulations by a Novel Dissolution Model for Assessing Intraluminal Drug Release in Individual Subjects.
    Karkossa F; Klein S
    J Pharm Sci; 2018 Jun; 107(6):1680-1689. PubMed ID: 29499277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of ethanol on aspirin release from hypromellose matrices.
    Roberts M; Cespi M; Ford JL; Dyas AM; Downing J; Martini LG; Crowley PJ
    Int J Pharm; 2007 Mar; 332(1-2):31-7. PubMed ID: 17084050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ethanol on the release of morphine sulfate from Oramorph SR tablets.
    Barkin RL; Shirazi D; Kinzler E
    Am J Ther; 2009; 16(6):482-6. PubMed ID: 19770796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diclofenac sodium multisource prolonged release tablets--a comparative study on the dissolution profiles.
    Bertocchi P; Antoniella E; Valvo L; Alimonti S; Memoli A
    J Pharm Biomed Anal; 2005 Apr; 37(4):679-85. PubMed ID: 15797788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethanol-drug absorption interaction: potential for a significant effect on the plasma pharmacokinetics of ethanol vulnerable formulations.
    Lennernäs H
    Mol Pharm; 2009; 6(5):1429-40. PubMed ID: 19655809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Release of 5-Aminosalicylic Acid (5-ASA) from Mesalamine Formulations at Various pH Levels.
    Abinusawa A; Tenjarla S
    Adv Ther; 2015 May; 32(5):477-84. PubMed ID: 25951927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability of controlled release mesalazine (5-ASA) preparations.
    Rasmussen SN
    J Gastroenterol; 1995 Nov; 30 Suppl 8():112-4. PubMed ID: 8563869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and Optimization of a Novel Prolonged Release Formulation to Resist Alcohol-Induced Dose Dumping.
    Gujjar CY; Rallabandi BC; Gannu R; Deulkar VS
    AAPS PharmSciTech; 2016 Apr; 17(2):350-7. PubMed ID: 26162975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissolution of mesalazine modified release tablets under standard and bio-relevant test conditions.
    Garbacz G; Rappen GM; Koziolek M; Weitschies W
    J Pharm Pharmacol; 2015 Feb; 67(2):199-208. PubMed ID: 25557626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irregular absorption profiles observed from diclofenac extended release tablets can be predicted using a dissolution test apparatus that mimics in vivo physical stresses.
    Garbacz G; Wedemeyer RS; Nagel S; Giessmann T; Mönnikes H; Wilson CG; Siegmund W; Weitschies W
    Eur J Pharm Biopharm; 2008 Oct; 70(2):421-8. PubMed ID: 18582568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissolution of Commercially Available Mesalamine Formulations at Various pH Levels.
    Tenjarla S
    Drugs R D; 2015 Jun; 15(2):211-5. PubMed ID: 26115756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: inter-individual variability of cimetidine absorption.
    Willmann S; Edginton AN; Kleine-Besten M; Jantratid E; Thelen K; Dressman JB
    J Pharm Pharmacol; 2009 Jul; 61(7):891-9. PubMed ID: 19589231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.